ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ADC Therapeutics secures FDA priority review for Lonca in diffuse large B-cell lymphoma
November 24, 2020ADC Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and ... -
ADC Therapeutics begins phase 2 portion of LOTIS 3 trial of Lonca, ibrutinibhave combo
July 22, 2020ADC Therapeutics announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in combination with ibrutinib in patients with relapsed ... -
ADC Therapeutics Appoints Jennifer Creel as CFO
April 22, 2020ADC Therapeutics SA, a clinical-stage oncology-focused biotech focused on the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors. -
ADC Therapeutics, Adagene Ink License Agreement
April 26, 2019ADC Therapeutics, an oncology drug discovery and development company that specializes in antibody drug conjugates (ADCs), and Adagene Inc., an antibody engineering and discovery company ...
Pharma Sources Insight January 2025
